Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone Eye Drops for Proliferative Retinopathy of Prematurity
2020-004933-19Phase 3Active
- Sponsor
- Region Västra Götaland
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexamethasone in retinopathy of prematurity (ROP) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Reduced frequency of infants treated with laser and/or AntiVEGF for Type 1 ROP. Started Jan 2021; status: active.
02
Drugs
dexamethasone
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2020-004933-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004933-19.